UNITED ~~STATES~~STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

SECURITIESFORM AND EXCHANGE COMMISSION8-K

~~WASHINGTON,~~CURRENT ~~D.C. 20549~~REPORT

~~FORM~~Pursuant ~~8-K~~to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~CURRENT~~Date ~~REPORT~~of Report (Date of earliest event reported): August 12, 2025

~~Pursuant~~PROKIDNEY ~~to Section 13 or 15(d)~~CORP.

(Exact name of ~~the~~Registrant ~~Securities~~as ~~Exchange~~Specified ~~Act~~in ofIts ~~1934~~Charter)

Date of Report (Date of earliest event reported): July 15, 2025


Delaware	001-40560	98-1586514
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2000 Frontis Plaza Blvd. Suite 250
Winston-Salem, North Carolina		27103
(Address of Principal Executive Offices)		(Zip Code)

~~PROKIDNEY~~Registrant’s ~~CORP.~~Telephone Number, Including Area Code: 336 999-7019

(~~Exact~~Former ~~name~~Name ofor ~~Registrant~~Former asAddress, ~~Specified~~if inChanged ~~Its~~Since ~~Charter~~Last Report)

Delaware		001-40560		98-1586514
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

2000 Frontis Plaza Blvd. Suite 250
Winston-Salem, North Carolina		27103
(Address of Principal Executive Offices)		(Zip Code)

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

~~Registrant’s~~☐Soliciting ~~Telephone~~material ~~Number,~~pursuant ~~Including~~to ~~Area~~Rule ~~Code:~~14a-12 ~~336~~under ~~999~~the Exchange Act (17 CFR 240.14a-~~7019~~12)

~~(Former~~☐Pre-commencement ~~Name~~communications orpursuant ~~Former~~to ~~Address,~~Rule if14d-2(b) ~~Changed~~under ~~Since~~the ~~Last~~Exchange ~~Report~~Act (17 CFR 240.14d-2(b))

~~Check the appropriate box below if the Form 8~~☐Pre-Kcommencement ~~filing~~communications ispursuant ~~intended~~ to ~~simultaneously~~Rule ~~satisfy~~13e-4(c) ~~the~~under ~~filing obligation of~~ the ~~registrant~~Exchange ~~under~~Act ~~any~~(17 ofCFR ~~the following provisions:~~240.13e-4(c))

☐Securities ~~Written~~registered ~~communications~~ pursuant to ~~Rule~~Section ~~425~~12(b) ~~under~~of the ~~Securities~~ Act ~~(17 CFR 230.425)~~:

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, $0.0001 par value per share	PROK	The Nasdaq Stock Market

☐Indicate ~~Pre-commencement~~by ~~communications~~check ~~pursuant~~mark towhether the registrant is an emerging growth company as defined in Rule ~~14d-2~~405 of the Securities Act of 1933 (b§ 230.405 of this chapter) ~~under~~or Rule 12b-2 of the Securities Exchange Act ~~(17~~of ~~CFR~~1934 (§ 240.~~14d~~12b-2(b of this chapter)).

☐Emerging ~~Pre-commencement~~growth ~~communications~~company ~~pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))~~☒

~~Securities~~If ~~registered~~an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 1213(ba) of the Exchange Act:. ☐

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A common stock, $0.0001 par value per share		PROK		The Nasdaq Stock Market

Item 2.02 Results of Operations and Financial Condition.

~~Indicate~~On byAugust ~~check~~12, ~~mark~~2025, ~~whether~~ProKidney Corp. (the ~~registrant~~"Company") isissued ana ~~emerging~~press ~~growth~~release ~~company~~to asannounce ~~defined~~its infinancial ~~Rule~~results ~~405~~for of the ~~Securities~~quarter ~~Act~~ended ofJune ~~1933~~30, ~~(§ 230~~2025.~~405~~ ofA ~~this~~copy ~~chapter) or Rule 12b-2~~ of the ~~Securities~~press ~~Exchange~~release ~~Act~~is offurnished ~~1934~~as ~~(§ 240.12b-2~~Exhibit ~~of this chapter)~~99.1.

~~Emerging~~The ~~growth~~information ~~company~~in ☒this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

IfItem an9.01 emergingFinancial growthStatements company,and indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange ActExhibits. ☐

~~Item 7.01~~(d) ~~Regulation FD Disclosure.~~ Exhibits

Presentation



Exhibit No.	Description
99.1	Press Release dated August 12, 2025
104	Cover Page Interactive Data File (embedded within Inline XBRL document)

Certain information concerning the business, clinical studies, development plans, financial position and related matters of ProKidney Corp. (the “Company”) has been made available on our website at https://investors.prokidney.com/news-events/events-and-presentations. Representatives of the Company, including senior management, may use this presentation, in whole or in part, from time to time when interacting with investors and analysts, among others. The Presentation is also attached hereto as Exhibit 99.2. SIGNATURES

~~The~~Pursuant ~~information contained in the presentation is summary information that is intended~~ to ~~be considered in~~ the ~~context~~requirements of the ~~Company’s filings with the U.S.~~ Securities ~~and~~ Exchange ~~Commission~~Act ~~(“SEC”)~~of ~~and other public announcements that the Company may make~~1934, ~~by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise~~ the ~~information~~registrant ~~contained~~has induly ~~the~~caused ~~presentation~~this ~~except~~report ~~as required by applicable law, although the Company may do so from time~~ to ~~time as its management believes is warranted. Any such updating may~~ be ~~made~~signed ~~through~~on ~~the~~its ~~filing~~behalf ofby ~~other reports or documents with~~ the ~~SEC,~~undersigned ~~through~~hereunto ~~press~~duly ~~releases, or through other public disclosure~~authorized. ~~The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K.~~

Press Release


			PROKIDNEY CORP.

Date:	August 12, 2025	By:	/s/ James Coulston
			James Coulston Chief Financial Officer

On July 15, 2025, the Company issued a press release announcing confirmation of alignment with the U.S. Food and Drug Administration on the accelerated approval pathway for rilparencel. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

The information set forth in the first and second paragraphs of the Company’s press release referred to in Item 7.01 and included as Exhibit 99.1 hereto above is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits relating to Item 7.01 are furnished and not filed:

Exhibit No.		Description
99.1		Press Release dated July 15, 2025
99.2		Investor Presentation
104		Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		PROKIDNEY CORP.
Date: July 15, 2025	By:	/s/ Todd Girolamo
		Todd Girolamo Chief Legal Officer

Filing Compare · PROKIDNEY CORP.